UP!

CLVS $7.13   View long term graphs

Clovis Oncology is a mid-sized pharmaceutical company which mainly markets products for treatment in oncology. Clovis was founded in 2009 and is headquartered in Boulder, Colorado. The company is a publicly traded company on NASDAQ under the symbol "CLVS" and is in the NASDAQ Biotechnology Index with several products in its product pipeline.

Its products include:

The company was developing rociletinib, as a treatment for non-small cell lung cancer. A phase III trial was completed in April 2016 and had it been approved it would have competed with AstraZeneca's Tagrisso (osimertinib). According to the company web site as of November 2016 studies on the drug are no longer accepting new patients, but Clovis would continue to supply the drug to patients whose physicians had recommended continued treatment.

Rucaparib is a PARP inhibitor in Phase II and III clinical trials for advanced ovarian cancer.

Lucitanib is a VEGFR inhibitor. it is also an inhibitor of FGFR1 and FGFR2 and has undergone clinical trials for advanced solid tumors.

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q3 2020 2020-11-05 Future report Set alerts
Q2 2020 2020-08-06 -1.15 -1.15
Q1 2020 2020-05-05 -1.39 -1.39
Q4 2019 2020-02-24 -1.81 -1.81
Q3 2019 2019-11-07 -1.72 -1.72
Q2 2019 2019-08-01 -2.27 -2.27
Q1 2019 2019-05-07 -1.63 -1.63
Q4 2018 2019-02-26 -1.88 -1.88
Q3 2018 2018-10-30 -1.71 -1.71
Q2 2018 2018-08-01 -1.94 -1.94

Ratings

2016-07-12 Reiterated Rating Credit Suisse Group AG Hold
2016-06-30 Reiterated Rating Stifel Nicolaus Buy $30.00
2016-06-29 Reiterated Rating Piper Jaffray Hold $14.00
2016-06-29 Reiterated Rating Piper Jaffray Cos. Hold $14.00
2016-06-08 Reiterated Rating Credit Suisse Hold
2016-06-08 Reiterated Rating Credit Suisse Group AG Hold
2016-05-09 Lower Price Target WallachBeth Capital Hold $30.00 to $22.00
2016-05-08 Reiterated Rating Piper Jaffray Hold
2016-04-18 Initiated Coverage Credit Suisse Outperform
2016-04-13 Reiterated Rating Mizuho Hold
2016-04-13 Reiterated Rating Janney Montgomery Scott Buy
2016-04-13 Downgrade Credit Suisse Outperform to Neutral $32.00 to $14.00
2016-04-13 Downgrade JPMorgan Chase & Co. Overweight to Neutral $42.00 to $15.00
2016-04-12 Reiterated Rating Stifel Nicolaus Buy $30.00
2016-04-12 Reiterated Rating Piper Jaffray Neutral $18.00
2016-04-11 Lower Price Target Mizuho Neutral $21.00 to $15.00
2016-04-05 Reiterated Rating Piper Jaffray Hold $18.00
2016-04-04 Initiated Coverage Piper Jaffray Neutral $28.00 to $18.00
2016-03-28 Boost Price Target Leerink Swann Outperform $104.00 to $110.00
2016-02-29 Lower Price Target Mizuho Neutral $23.00 to $21.00
2016-02-26 Reiterated Rating JPMorgan Chase & Co. Buy $42.00
2016-02-26 Reiterated Rating Stifel Nicolaus Buy $45.00 to $30.00
2016-02-22 Lower Price Target Goldman Sachs $23.00 to $19.00
2016-02-22 Lower Price Target Goldman Sachs Group Inc. $23.00 to $19.00
2016-01-25 Lower Price Target Mizuho Neutral $35.00 to $23.00
2016-01-20 Initiated Coverage Credit Suisse Outperform $32.00
2015-12-17 Initiated Coverage Janney Montgomery Scott Buy $50.00
2015-11-17 Reiterated Rating JPMorgan Chase & Co. Overweight $110.00 to $42.00
2015-11-17 Downgrade WallachBeth Capital Buy to Hold $135.00 to $30.00
2015-11-17 Downgrade Goldman Sachs Buy to Neutral $123.00 to $23.00
2015-11-16 Reiterated Rating Stifel Nicolaus Buy $140.00 to $45.00
2015-11-16 Downgrade Mizuho Buy to Neutral $114.00 to $35.00
2015-11-16 Lower Price Target Piper Jaffray Neutral $92.00 to $28.00
2015-11-06 Boost Price Target Mizuho Buy $103.00 to $114.00
2015-11-06 Boost Price Target JPMorgan Chase & Co. Overweight $103.00 to $110.00
2015-09-10 Boost Price Target WallachBeth Capital Buy $115.00 to $134.00
2015-09-09 Reiterated Rating Piper Jaffray Hold $77.00 to $92.00
2015-09-08 Reiterated Rating Mizuho Buy $103.00
2015-09-02 Reiterated Rating JPMorgan Chase & Co. Buy
2015-08-10 Reiterated Rating JPMorgan Chase & Co. Buy $103.00
2015-08-07 Reiterated Rating Mizuho Buy $103.00
2015-07-20 Lower Price Target Piper Jaffray Neutral $100.00 to $77.00
2015-07-20 Upgrade Goldman Sachs Buy to Conviction-Buy $117.00 to $110.00
2015-07-02 Reiterated Rating Mizuho Buy
2015-06-15 Boost Price Target WallachBeth Capital Buy $85.00 to $115.00
2015-06-01 Reiterated Rating JPMorgan Chase & Co. Buy
2015-06-01 Reiterated Rating Mizuho Buy $100.00 to $103.00
2015-05-18 Boost Price Target Stifel Nicolaus $125.00
2015-05-16 Reiterated Rating Stifel Nicolaus Buy $90.00 to $125.00
2015-05-15 Downgrade Piper Jaffray Overweight to Neutral $100.00
2015-05-09 Reiterated Rating Goldman Sachs Buy
2015-05-08 Reiterated Rating JPMorgan Chase & Co. Overweight $92.00
2015-04-13 Upgrade Goldman Sachs Neutral to Buy $68.00 to $117.00
2015-04-07 Reiterated Rating JPMorgan Chase & Co. Overweight
2015-02-26 Reiterated Rating JPMorgan Chase & Co. Overweight $92.00
2015-02-26 Boost Price Target Stifel Nicolaus Buy $75.00 to $90.00
2015-02-23 Boost Price Target Citigroup Inc. Neutral $60.00 to $85.00
2014-11-07 Reiterated Rating Citigroup Inc. Neutral $53.00 to $60.00
2014-11-07 Reiterated Rating Stifel Nicolaus Buy $50.00 to $75.00
2014-08-08 Initiated Coverage Leerink Swann Outperform $100.00
2014-06-05 Upgrade Stifel Hold to Buy $50
2014-06-05 Upgrade Stifel Nicolaus Hold to Buy $50.00
2014-06-04 Lower Price Target Goldman Sachs Neutral $85.00 to $50.00
2014-06-03 Downgrade Citigroup Inc. Buy to Neutral $109.00 to $53.00
2014-05-20 Reiterated Rating WallachBeth Capital Buy $85.00
2014-04-30 Initiated WallachBeth Buy $85
2014-04-30 Initiated Coverage WallachBeth Capital Buy $85.00
2014-03-24 Initiated Coverage Goldman Sachs Neutral $90.00
2014-03-05 Boost Price Target Credit Suisse $78.00 to $100.00
2014-02-28 Boost Price Target Leerink Swann $104.00 to $110.00
2014-01-28 Boost Price Target Mizuho Buy $90.00 to $100.00
2013-11-15 Initiated Coverage HC Wainwright Neutral $55.00
2013-09-27 Reiterated Rating Leerink Swann Outperform $88.00
2013-09-20 Initiated Coverage Citigroup Inc. Buy
2013-06-25 Initiated Mizuho Buy $90
2016-07-12 Reiterated Rating Credit Suisse Group AG Hold
2016-06-30 Reiterated Rating Stifel Nicolaus Buy $30.00
2016-06-29 Reiterated Rating Piper Jaffray Hold $14.00
2016-06-29 Reiterated Rating Piper Jaffray Cos. Hold $14.00
2016-06-08 Reiterated Rating Credit Suisse Hold

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
KRAMLICH C RICHARD 10.07%  (3419671) CLVS / ECHO / HPTX / INWK / SIVB / TRGT / TSRO / XOOM / ZHNE /
DOMAIN PARTERS VII L P 7.60%  (2581745) AKAO / CADX / CLVS / ESPR / EVOK / OREX / RGDO / TNDM / ZGNX /
NEW ENTERPRISE ASSOCIATES 13 LP 6.71%  (2279781) CLVS / CRCM / CVT / EPZM / GLYC / HIVE / ROKA / TSRO /
MAHAFFY PATRICK J President and CEO 2.77%  (940787) CLVS / FLXN / OREX /
McKinley Edward J 0.64%  (215815) CLVS /
IVERS-READ GILLIAN C See Remarks 0.54%  (182995) BPTH / CLVS /
MAST ERLE T Executive VP and CFO 0.40%  (135583) CLVS / RCPT / ZGNX /
Allen Andrew R See Remarks 0.30%  (101919) CLVS / EPZM /
DOVEY BRIAN H 0.15%  (51013) ACHN / AKAO / CADX / CLVS / DRNA / DRTX / ESPR / EVOK / OCRX / OREX / OTIC / RGDO / TNDM / VCYT / ZGNX /
VITULLO NICOLE 0.15%  (51013) ACHN / AKAO / CADX / CLVS / CPXX / DRNA / DRTX / ESPR / EVOK / MRNS / OCRX / OREX / RGDO / TNDM / VCYT / ZGNX /
TREU JESSE I 0.15%  (51013) ACHN / AKAO / ALDX / CADX / CLVS / DRNA / DRTX / ESPR / EVOK / OCRX / OREX / RGDO / TNDM / VCYT / ZGNX /
Halak Brian K 0.15%  (51013) ACHN / AKAO / ALIM / CADX / CLVS / DRNA / DRTX / ESPR / EVOK / OCRX / OREX / TNDM / VCYT / VNDA / ZGNX /
SCHOEMAKER KATHLEEN K 0.15%  (51013) ACHN / AKAO / CADX / CLVS / DRNA / DRTX / ESPR / EVOK / OCRX / OREX / RGDO / TNDM / VCYT / ZGNX /
DP VII ASSOCIATES LP 0.13%  (44034) AKAO / CADX / CLVS / ESPR / EVOK / OREX / TNDM / ZGNX /
ATWOOD BRIAN G 0.08%  (25577) CADX / CLVS / FPRX / IMDZ / PZRX / VCYT /
KLINGENSTEIN PAUL H 0.08%  (25509) ANAC / CLVS / CNAT / ETRM /
Versant Venture Capital IV, L.P. 0.03%  (10200) CLVS /
Rolfe Lindsey See Remarks 0.03%  (9789) CLVS /
BLAIR JAMES C 0.03%  (9404) ACHN / AKAO / CADX / CLVS / DRNA / DRTX / ESPR / EVOK / OCRX / OREX / RGDO / TNDM / VCYT / ZGNX /
SPICKSCHEN THORLEF 0.02%  (7618) CLVS /
Hooks Corwin Dale See Remarks 0.01%  (4026) CLVS /
MUEHL DANIEL W See Remarks 0.01%  (3953) CLVS /
BASKETT FOREST 0.01%  (2483) ABIO / ADNC / AKAO / ARDX / AVEO / CLVS / CRCM / CVT / DATA / ECHO / EPZM / FIO / HIVE / HPTX / INWK / LOXO / ONTY / ROKA / SNSS / SUPN / SURF / SYBX / TSRO / XOOM /
BARRIS PETER J 0.01%  (2483) ABIO / ADNC / AKAO / ARDX / AVEO / CLVS / CRCM / CVT / DATA / ECHO / EPZM / GLYC / GRPN / HIVE / HPTX / INWK / LOXO / ONTY / ROKA / SNSS / SUPN / SURF / SYBX / TRGT / TSRO / VTAE / WIFI / XOOM / ZHNE /
SANDELL SCOTT D 0.01%  (2483) ABIO / ADNC / AKAO / ARDX / AVEO / CLVS / CRCM / CVT / DATA / ECHO / EPZM / FIO / GLYC / HIVE / HPTX / INWK / LOXO / ONTY / ROKA / SNSS / SUPN / SURF / SYBX / TRGT / TSRO / VTAE / WDAY / WIFI / XOOM /
DRANT RYAN D 0.01%  (2483) ADNC / ARDX / CLVS / CRCM / CVT / DATA / ECHO / EPZM / HIVE / HPTX / INWK / LOXO / ROKA / SNSS / TSRO / XOOM /

Comments